Trials / Completed
CompletedNCT03963232
A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Galcanezumab in Patients With Episodic Migraine-the Persist Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 520 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The reason for this study is to see if the drug galcanezumab is safe and effective in participants with episodic migraine. The study will last about 53 weeks and may include up to 12 visits.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Galcanezumab | Administered SC |
| DRUG | Placebo | Administered SC |
Timeline
- Start date
- 2019-07-30
- Primary completion
- 2021-07-27
- Completion
- 2022-03-11
- First posted
- 2019-05-24
- Last updated
- 2023-03-28
- Results posted
- 2022-08-19
Locations
40 sites across 3 countries: China, India, Russia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03963232. Inclusion in this directory is not an endorsement.